Sign In
Buy REGN
$618.95
+16.03 (+2.66%)
At Close: Jun 03, 2026
Aaron Wealth Advisors LLC Takes $449,000 Position in Regeneron Pharmaceuticals, Inc. $REGN
03:09am, Friday, 19'th Dec 2025
Aaron Wealth Advisors LLC purchased a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) in the third quarter, according to its most recent filing with the Securities and Exchang
Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Acquired Rep. Gilbert Ray Cisneros, Jr.
02:06am, Thursday, 18'th Dec 2025
Representative Gilbert Ray Cisneros, Jr. (D-California) recently bought shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN). In a filing disclosed on December 15th, the Representative disclosed t
2 Reasons to Buy Regeneron Stock Like There's No Tomorrow
10:01am, Saturday, 13'th Dec 2025
Regeneron is finding ways to deal with the increased competition to one of its key growth drivers. The company is also developing newer medicines that will improve its financial results.
Regeneron (REGN) Just Flashed Golden Cross Signal: Do You Buy?
10:35am, Friday, 12'th Dec 2025
From a technical perspective, Regeneron (REGN) is looking like an interesting pick, as it just reached a key level of support. REGN recently overtook the 20-day moving average, and this suggests a sho
Calls of the Day: Regeneron, Booking Holdings, General Dynamics and Fiserv
01:31pm, Wednesday, 10'th Dec 2025
The Investment Committee debate the latest Calls of the Day.
Regeneron Pharmaceuticals, Inc. (REGN) Discusses Lynozyfic Development Strategy and Pipeline Opportunities in Multiple Myeloma Transcript
12:42pm, Wednesday, 10'th Dec 2025
Regeneron Pharmaceuticals, Inc. (REGN) Discusses Lynozyfic Development Strategy and Pipeline Opportunities in Multiple Myeloma Transcript
Health Rounds: Regeneron drug wipes out residual multiple myeloma cells in small trial
12:20pm, Wednesday, 10'th Dec 2025
A recently approved antibody drug from Regeneron Pharmaceuticals eradicates residual traces of multiple myeloma after initial treatments, potentially allowing patients to avoid grueling bone marrow tr
Regeneron Pharmaceuticals: Is Wall Street Finally Paying Attention?
02:46pm, Monday, 08'th Dec 2025
Regeneron Pharmaceuticals once again beat consensus EPS and revenue estimates by a wide margin. Moreover, as of September 30, Regeneron had about $2.2 billion remaining under its authorized share repu
California Public Employees Retirement System Sells 158,734 Shares of Regeneron Pharmaceuticals, Inc. $REGN
04:44am, Monday, 08'th Dec 2025
California Public Employees Retirement System reduced its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 33.5% in the second quarter, according to its most recent 13F filing w
Bank of Nova Scotia Purchases 126,689 Shares of Regeneron Pharmaceuticals, Inc. $REGN
03:34am, Monday, 08'th Dec 2025
Bank of Nova Scotia lifted its position in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 103.3% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange
All three dose groups (50 mg, 100 mg and 200 mg) showed impressive monotherapy efficacy, with VGPR+ (very good partial response or better) of ≥70% despite limited follow-up; evidence shows that thes
Regeneron's experimental therapy combo effective in untreated cancer patients
09:33am, Saturday, 06'th Dec 2025
Regeneron said on Saturday its experimental cancer combination therapy was effective and showed disappearance of the disease in previously untreated patients with a type of blood cancer in the first p
Regeneron Pharmaceuticals, Inc. $REGN Position Cut by Groupe la Francaise
04:42am, Thursday, 04'th Dec 2025
Groupe la Francaise lowered its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 45.7% in the undefined quarter, according to its most recent disclosure with the SEC. The fund o
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Given Average Rating of “Moderate Buy” by Analysts
01:41am, Thursday, 04'th Dec 2025
Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN - Get Free Report) have earned an average rating of "Moderate Buy" from the twenty-eight research firms that are covering the stock, MarketBeat
Regeneron Pharmaceuticals, Inc. (REGN) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
02:13pm, Wednesday, 03'rd Dec 2025
Regeneron Pharmaceuticals, Inc. (REGN) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
